Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Parvinder Kaur

Showing results (71-80 of 85) with videos related to

Pageof 9
Sort By:
Journal of Medicinal Chemistry|May 14, 2014
Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activityManoranjan Panda, Sreekanth Ramachandran, Vasanthi Ramachandran, et al.
Journal of Chemotherapy (Florence, Italy)|February 21, 2025
Investigation of chemotherapy-induced cardiac dysfunction in breast cancerSai Harini Chandrasekaran, Pugazhendi Inban, Reeju Maharjan, et al.
ACS Medicinal Chemistry Letters|September 16, 2014
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosisMaruti Naik, Sandeep Ghorpade, Lalit Kumar Jena, et al.
Journal of Medicinal Chemistry|June 27, 2014
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component systemEknath Bellale, Maruti Naik, Varun V B, et al.
Tuberculosis (Edinburgh, Scotland)|July 2, 2021
A multi-targeting pre-clinical candidate against drug-resistant tuberculosisParvinder Kaur, Vijay Potluri, Vijay Kamal Ahuja, et al.
Ebiomedicine|January 1, 2026
Multicentre preclinical profiling of apramycin for the treatment of nontuberculous mycobacteriaMinh-Vu H Nguyen, Michel Plattner, Deepshikha Verma, et al.
ACS Chemical Biology|July 19, 2014
Pyrazolopyrimidines establish MurC as a vulnerable target in Pseudomonas aeruginosa and Escherichia coliShahul Hameed P, Praveena Manjrekar, Murugan Chinnapattu, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2014
Assessment of Mycobacterium tuberculosis pantothenate kinase vulnerability through target knockdown and mechanistically diverse inhibitorsB K Kishore Reddy, Sudhir Landge, Sudha Ravishankar, et al.
Bioorganic & Medicinal Chemistry|December 9, 2015
Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidaseSudhir Landge, Amrita B Mullick, Kavitha Nagalapur, et al.
Nature Communications|March 5, 2024
Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteriaLukas Junk, Volker M Schmiedel, Somraj Guha, et al.
Pageof 9

Showing results (71-80 of 85) with videos related to

Sort By:
Pageof 9
Journal of Medicinal Chemistry|May 14, 2014
Discovery of pyrazolopyridones as a novel class of noncovalent DprE1 inhibitor with potent anti-mycobacterial activityManoranjan Panda, Sreekanth Ramachandran, Vasanthi Ramachandran, et al.
Journal of Chemotherapy (Florence, Italy)|February 21, 2025
Investigation of chemotherapy-induced cardiac dysfunction in breast cancerSai Harini Chandrasekaran, Pugazhendi Inban, Reeju Maharjan, et al.
ACS Medicinal Chemistry Letters|September 16, 2014
2-Phenylindole and Arylsulphonamide: Novel Scaffolds Bactericidal against Mycobacterium tuberculosisMaruti Naik, Sandeep Ghorpade, Lalit Kumar Jena, et al.
Journal of Medicinal Chemistry|June 27, 2014
Diarylthiazole: an antimycobacterial scaffold potentially targeting PrrB-PrrA two-component systemEknath Bellale, Maruti Naik, Varun V B, et al.
Tuberculosis (Edinburgh, Scotland)|July 2, 2021
A multi-targeting pre-clinical candidate against drug-resistant tuberculosisParvinder Kaur, Vijay Potluri, Vijay Kamal Ahuja, et al.
Ebiomedicine|January 1, 2026
Multicentre preclinical profiling of apramycin for the treatment of nontuberculous mycobacteriaMinh-Vu H Nguyen, Michel Plattner, Deepshikha Verma, et al.
ACS Chemical Biology|July 19, 2014
Pyrazolopyrimidines establish MurC as a vulnerable target in Pseudomonas aeruginosa and Escherichia coliShahul Hameed P, Praveena Manjrekar, Murugan Chinnapattu, et al.
Antimicrobial Agents and Chemotherapy|April 2, 2014
Assessment of Mycobacterium tuberculosis pantothenate kinase vulnerability through target knockdown and mechanistically diverse inhibitorsB K Kishore Reddy, Sudhir Landge, Sudha Ravishankar, et al.
Bioorganic & Medicinal Chemistry|December 9, 2015
Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-β-D-ribose 2'-oxidaseSudhir Landge, Amrita B Mullick, Kavitha Nagalapur, et al.
Nature Communications|March 5, 2024
Homo-BacPROTAC-induced degradation of ClpC1 as a strategy against drug-resistant mycobacteriaLukas Junk, Volker M Schmiedel, Somraj Guha, et al.
Pageof 9